Related Experiment Videos
IKr channel blockers: novel antiarrhythmic agents
1Department of Pharmacology, College of Veterinary Medicine and School of Agricultural Biotechnology, Seoul National University, Seoul, Korea.
Current Medicinal Chemistry. Cardiovascular and Hematological Agents
|August 26, 2004
Summary
Developing I(Kr) channel blockers for arrhythmias shows promise, but all current drugs carry a risk of torsade de pointes. Future research aims to improve their safety profile and efficacy.
Area of Science:
- Cardiovascular Pharmacology
- Electrophysiology
- Drug Development
Background:
- Extensive research targets I(Kr) channel blockers for atrial and ventricular fibrillation treatment.
- Selective I(Kr) blockade is considered safe regarding total mortality in arrhythmia patients.
Purpose of the Study:
- To review current I(Kr) channel blockers, their mechanisms, and proarrhythmic potential.
- To identify strategies for developing safer and more effective antiarrhythmic agents targeting I(Kr).
Main Methods:
- Review of existing literature on I(Kr) channel blockers.
- Analysis of drug profiles, including selectivity, action potential duration prolongation, and frequency dependence.
- Assessment of proarrhythmic potential, specifically torsade de pointes induction.
Main Results:
- Dofetilide and KCB-328 selectively block I(Kr), increasing action potential duration (APD).
- Other blockers like ibutilide and dronedarone affect multiple cardiac channels.
- All I(Kr) blockers exhibit some degree of proarrhythmic potential, varying in intensity.
Conclusions:
- Optimizing I(Kr) blocker properties, such as HERG block kinetics and balance with Ca++ channel activity, is crucial for reducing proarrhythmia.
- Further research is needed to discover novel compounds with improved safety and efficacy for ventricular arrhythmias.